DBV Technologies S.A. Overview
Pro stress-test →DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. The company's flagship product is the Viaskin patch platform, with positive topline Phase 3 VITESSE results for the VIASKIN® Peanut Patch in children aged 4 to 7 years, supporting a planned Biologics License Application submission in the United States in the first half of the year.
Strategic Profile
Pro stress-test →The company is advancing the COMFORT Toddlers safety trial in children aged 1 to 3 years and THRIVE, a first-of-its-kind study in infants aged 6 to 12 months. DBV raised $386.2 million in capital between March 2025 and January 2026, providing funding into the second quarter of 2027, including the potential U.S. launch of the VIASKIN Peanut Patch.
Competitive Landscape
Pro stress-test →DBV operates in the allergy immunotherapy space competing against companies developing oral immunotherapy products and traditional pharmaceutical allergen treatments. Key peer biotech companies in similar clinical-stage niches include Omeros, Annexon, and Candel Therapeutics. DBV's patch-based platform differentiates from oral approaches, particularly in pediatric populations where ease of administration is critical.
Industry Context
DBV Technologies S.A. operates in Biopharmaceutical/Food Allergy Immunotherapy.
Key facts
Founded: 2002 · Headquarters: Châtillon, France · Employees: N/A · Revenue: N/A · Market cap: $947M